Radezolid

Radezolid

Clinical data
Routes of administration	Intravenous infusion, oral
ATC code	none
Legal status
Legal status	Investigational
Identifiers
IUPAC name N-{[(5S)-3-(2-fluoro-4′-{[(1H-1,2,3-triazol-5-ylmethyl)amino]methyl}biphenyl-4-yl)-2-oxo-1,3-oxazolidin-5-yl]methyl}acetamide
JSmol)	Interactive image
SMILES CC(=O)NC[C@H]1CN(C(=O)O1)c2ccc(c(c2)F)c3ccc(cc3)CNCc4cnn[nH]4

Radezolid (

Further reading

• Zhou J, Bhattacharjee A, Chen S, et al. (December 2008). "Design at the atomic level: design of biaryloxazolidinones as potent orally active antibiotics". Bioorg. Med. Chem. Lett. 18 (23): 6175–8.
  PMID 18947996
  .
• Skripkin E, McConnell TS, DeVito J, et al. (October 2008). "Rχ-01, a new family of oxazolidinones that overcome ribosome-based linezolid resistance". Antimicrob. Agents Chemother. 52 (10): 3550–7.
  PMID 18663023
  .
• Lawrence L, Danese P, DeVito J, Franceschi F, Sutcliffe J (May 2008). "In vitro activities of the Rχ-01 oxazolidinones against hospital and community pathogens". Antimicrob. Agents Chemother. 52 (5): 1653–62.
  PMID 18316525
  .
• Hanselmann R, Job G, Johnson G, Lou R, Martynow JG, Reeve MM (2009). "Synthesis of an antibacterial compound containing a 1,4-substituted 1H-1,2,3-triazole- a scaleable [sic?] alternative to the "click" reaction"". Organic Process Research & Development. 14: 152–158.
  doi:10.1021/op900252a
  .
• Franceschi F, Duffy EM (March 2006). "Structure-based drug design meets the ribosome". Biochem. Pharmacol. 71 (7): 1016–25.
  PMID 16443192
  .
• Ohlsen K (November 2009). "Novel antibiotics for the treatment of Staphylococcus aureus". Expert Rev. Clin. Pharmacol. 2 (6): 661–72.
  S2CID 36016568
  .

This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it.

• v
• t
• e